Penalties and Appeals: Articles 160, 162 and 168 and the AED 1,000-1,000,000 Range
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Article 160 sets the fine range for establishments at AED 1,000 to 1,000,000; Article 162 provides that an appeal should be lodged within 15 days of the penalty notice, with the competent authority deciding within 30 days; Article 168 separately provides for supplementary penalties such as closure of business and confiscation. Our judgment is that the real cost in this combination is not the fine itself but the closure of business under Article 168: once an establishment is closed, the importers and the actual import records under Article 22 are interrupted along with it, which in turn drags in the revocation risk under Article 17. On the trade-off, the 15-day appeal window must be secured through a plan prepared in advance, not by assembling materials after the notice has been received.
- Article 160: fines on establishments range from AED 1,000 to 1,000,000, with no fixed tiers stated in the article.
- Article 162: appeal within 15 days of the penalty notice; the competent authority decides within 30 days.
- Article 168: supplementary penalties include closure of business and confiscation, which cut off supply rather than merely cost money.
- Compliance records built up in daily operations serve as mitigation evidence and are worth more than after-the-fact explanations.
2. Legal basis
The penalty and appeal provisions and the two articles most frequently implicated as sources of violations are set out in the table below.
| Federal Decree-Law on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments | Federal Decree-Law No. 38/2024 | Issued 2024-10-01; published in the Official Gazette 2024-10-14; effective 2025-01-02 | Article 160 | Fines on establishments of AED 1,000-1,000,000 |
| Federal Decree-Law on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments | Federal Decree-Law No. 38/2024 | Issued 2024-10-01; published in the Official Gazette 2024-10-14; effective 2025-01-02 | Article 162 | Appeal within 15 days; decision within 30 days |
| Federal Decree-Law on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments | Federal Decree-Law No. 38/2024 | Issued 2024-10-01; published in the Official Gazette 2024-10-14; effective 2025-01-02 | Article 168 | Supplementary penalties: closure of business, confiscation |
| Federal Decree-Law on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments | Federal Decree-Law No. 38/2024 | Issued 2024-10-01; published in the Official Gazette 2024-10-14; effective 2025-01-02 | Article 21 | Obligations of the rights holder; the article where high-frequency violations concentrate |
| Federal Decree-Law on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments | Federal Decree-Law No. 38/2024 | Issued 2024-10-01; published in the Official Gazette 2024-10-14; effective 2025-01-02 | Article 33 | Import and export permits and their revocation; a connected consequence of the supplementary penalties |
3. Expert insights
Insight 1: The upper and lower limits of the fine range differ by a factor of 1,000, and discretion turns on the circumstances. Our professional judgment is that Article 160 gives only a range and no fixed tiers; the specific tier is left to the Executive Regulation and case-by-case discretion. The reason is that the range runs from AED 1,000 to 1,000,000, and the outcome for the same violation can vary enormously depending on the circumstances. On the trade-off, the compliance record should be built into mitigation evidence, including documented vigilance reports, the actual import records under Article 22, and retained written replies to EDE enquiries; these materials are worth more at the discretion stage than after-the-fact explanations.
Insight 2: The 15-day appeal window is shorter than what domestic companies commonly expect. The judgment is that 15 days is a statutory deadline, and missing it most likely forfeits the remedy outright. The reason is that Article 162 expressly states both the appeal period and the 30-day decision period of the competent authority, forming a complete chain of remedy. On the trade-off, the appeal template, the authorized signature chain and the Arabic translation channel must be prepared in advance, and the date of receipt of an EDE penalty notice must be set as a mandatory control node.
Insight 3: The supplementary penalties of Article 168 bite harder than the fine. The judgment is that closure of business and confiscation cut the supply chain directly, and the loss accrues by the day and is irreversible. The reason is that the supplementary penalties target the qualification to operate and the products themselves, not a one-off amount. On the trade-off, the order of response during a dispute should be: first seek to avoid closure, then seek to reduce the scope of confiscation, and only last discuss the amount; closure is the last line of defense, not the opening position of a negotiation.
4. Practical recommendations
- Build a penalty response plan with the appeal template, the authorized signature chain and the Arabic translation channel pre-set, ready to activate on receipt of a notice.
- Set the date of receipt of the penalty notice as a mandatory control node, and back-plan the internal approvals and submission actions on the 15-day clock.
- Retain mitigation evidence in daily operations: documented vigilance reports, actual import records under Article 22, and written replies to EDE enquiries.
- During a dispute, give priority to avoiding closure, and set the response priorities in the order of closure, scope of confiscation, then amount.
- Ground the appeal materials in facts and records, attaching the corrective measures already completed and a timetable, rather than simply pleading difficulties.
- Agree with the responsible entity on a deadline for forwarding penalty notices, so that delay in transmission does not erode the 15-day window.
5. Verification checklist
- □ The penalty response plan is in effect, containing the appeal template, the authorized signature chain and the Arabic translation channel
- □ The date of receipt of a penalty notice is set as a mandatory control node, back-planned on 15 days
- □ Documented vigilance reports, actual import records and written EDE replies are archived as mitigation evidence
- □ The response priorities are fixed as no closure first, reduced confiscation scope second, amount last
- □ The appeal materials attach corrective measures and a timetable
- □ The deadline for forwarding penalty notices is written into the agreement with the responsible entity
- □ The scope to which the obligations under Article 21 and Article 33 are implicated in the grounds of the penalty has been verified
Further reading: Article No. 45, Change Management: Notification of Minor Changes and Re-Approval of Major Changes (Article 15); Article No. 46, Advertising and Promotion Approval: Articles 44-47 and Validity from 30 Days to 1 Year; Article No. 10, How to Use the One-Year Transition Period: The Effective Date, Rectification Obligations and the Start of Penalties.
Regulatory information verified as of October 29, 2026.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the United Arab Emirates. Our team manages adverse event reporting and recall coordination with MOHAP, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us